JP2024518375A5 - - Google Patents

Info

Publication number
JP2024518375A5
JP2024518375A5 JP2023567891A JP2023567891A JP2024518375A5 JP 2024518375 A5 JP2024518375 A5 JP 2024518375A5 JP 2023567891 A JP2023567891 A JP 2023567891A JP 2023567891 A JP2023567891 A JP 2023567891A JP 2024518375 A5 JP2024518375 A5 JP 2024518375A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
lipid
acceptable salt
compound
lipid composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023567891A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518375A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/027874 external-priority patent/WO2022235935A2/en
Publication of JP2024518375A publication Critical patent/JP2024518375A/ja
Publication of JP2024518375A5 publication Critical patent/JP2024518375A5/ja
Pending legal-status Critical Current

Links

JP2023567891A 2021-05-06 2022-05-05 Rna送達のためのイオン化可能なカチオン性脂質 Pending JP2024518375A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163185303P 2021-05-06 2021-05-06
US63/185,303 2021-05-06
PCT/US2022/027874 WO2022235935A2 (en) 2021-05-06 2022-05-05 Ionizable cationic lipids for rna delivery

Publications (2)

Publication Number Publication Date
JP2024518375A JP2024518375A (ja) 2024-05-01
JP2024518375A5 true JP2024518375A5 (cg-RX-API-DMAC10.html) 2025-05-13

Family

ID=83932495

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023567891A Pending JP2024518375A (ja) 2021-05-06 2022-05-05 Rna送達のためのイオン化可能なカチオン性脂質

Country Status (9)

Country Link
US (1) US20220389422A1 (cg-RX-API-DMAC10.html)
EP (1) EP4352038A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024518375A (cg-RX-API-DMAC10.html)
KR (1) KR20240008872A (cg-RX-API-DMAC10.html)
CN (2) CN121517316A (cg-RX-API-DMAC10.html)
AU (1) AU2022268975A1 (cg-RX-API-DMAC10.html)
CA (1) CA3219192A1 (cg-RX-API-DMAC10.html)
TW (1) TW202313557A (cg-RX-API-DMAC10.html)
WO (1) WO2022235935A2 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10526284B2 (en) 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US10383952B2 (en) 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
CN117098541A (zh) 2020-11-25 2023-11-21 阿卡格拉医药公司 用于递送核酸的脂质纳米粒及相关使用方法
AU2023379598A1 (en) * 2022-11-16 2025-05-08 Seawolf Therapeutics, Inc. Ionizable lipids and lipid nanoparticle compositions for the delivery of nucleic acids
WO2024192528A1 (en) * 2023-03-22 2024-09-26 Nanovation Therapeutics Inc. Ionizable anionic lipids
WO2024233750A1 (en) * 2023-05-10 2024-11-14 Arcturus Therapeutics, Inc. Ionizable cationic lipids for rna delivery
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN117482066B (zh) * 2023-11-02 2024-08-13 深圳市易瑞生物技术股份有限公司 脂质组合物和用于脂质组合物的化合物
WO2025117732A1 (en) * 2023-11-29 2025-06-05 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
IL328626A (en) 2023-12-15 2026-07-01 Capstan Therapeutics Inc Humanized anti-CD8 antibodies and their uses
WO2025134071A1 (en) * 2023-12-22 2025-06-26 Sanofi Malic and glutaric acid based ionizable lipids
CN117820149B (zh) * 2023-12-29 2025-01-07 北京剂泰医药科技有限公司 可电离脂质化合物
WO2025140421A1 (zh) * 2023-12-29 2025-07-03 北京剂泰医药科技有限公司 可电离脂质化合物及其在递送核酸疫苗中的用途
AU2025217182A1 (en) 2024-02-02 2026-08-06 Editas Medicine, Inc. MODIFIED GUIDE RNAs
WO2025213138A1 (en) 2024-04-05 2025-10-09 Editas Medicine, Inc. Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
CN121021427A (zh) * 2024-07-30 2025-11-28 广州市恒诺康医药科技有限公司 可离子化脂质及其用途
WO2026102260A1 (en) 2024-11-08 2026-05-15 Editas Medicine, Inc. Crispr-related methods and compositions targeting angiopoietin like 3 (angptl3)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2350296A4 (en) * 2008-11-17 2013-04-03 Enzon Pharmaceuticals Inc BRANCHED CATIONIC LIPIDS FOR THE SYSTEM FOR INTRODUCING NUCLEIC ACIDS
CA2853689C (en) * 2011-11-04 2020-06-30 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
DE21212055T1 (de) * 2011-12-07 2022-08-04 Alnylam Pharmaceuticals, Inc. Biologisch abbaubare lipide zur freisetzung von wirkstoffen
WO2013086322A1 (en) * 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
AU2013355258A1 (en) * 2012-12-07 2015-06-11 Alnylam Pharmaceuticals, Inc. Improved nucleic acid lipid particle formulations
WO2015011633A1 (en) * 2013-07-23 2015-01-29 Protiva Biotherapeutics, Inc. Compositions and methods for delivering messenger rna
US10383952B2 (en) * 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
JP7436990B2 (ja) * 2018-08-10 2024-02-22 国立大学法人京都大学 カチオン性脂質を用いた心筋細胞へのトランスフェクション方法
PL3908568T3 (pl) * 2019-01-11 2024-12-02 Acuitas Therapeutics, Inc. Lipidy do dostarczania środków czynnych w nanocząstkach lipidowych
EP3942050A4 (en) * 2019-03-19 2023-02-22 Arcturus Therapeutics, Inc. PROCEDURE FOR THE PRODUCTION OF LIPID-COATED RNA NANOPARTICLES
GB2600859B (en) * 2019-08-14 2024-04-03 Acuitas Therapeutics Inc Improved lipid nanoparticles for delivery of nucleic acids

Similar Documents

Publication Publication Date Title
JP2024546431A5 (cg-RX-API-DMAC10.html)
JP5095708B2 (ja) 核酸様化合物の送達
CA2622584C (en) Improvements in or relating to amphoteric liposomes
US7341738B2 (en) Lipid-encapsulated polyanionic nucleic acid
JP4203835B2 (ja) 全身への送達を増加させる新規のリポソーム複合体
EP3628335B1 (en) Lipidic nanoparticles for mrna delivery in the lungs
JP4951338B2 (ja) 脂質に封入された干渉rna
JP7595984B2 (ja) 脂質ナノ粒子
JP2022530018A5 (cg-RX-API-DMAC10.html)
JP2017536092A5 (cg-RX-API-DMAC10.html)
CN115515559B (zh) 信使rna的直肠递送
JP2003535832A (ja) ポリヌクレオチドおよび薬物の標的化リポソームへのカプセル化
TW201717914A (zh) 用於奈米顆粒冷凍乾燥形式的組成物及方法
KR100723852B1 (ko) 핵산 및 약물 전달용 중성-양이온성 지질
CA2223928A1 (en) Cationic lipid:dna complexes for gene targeting
Oku et al. Evaluation of drug targeting strategies and liposomal trafficking.
US6897200B1 (en) Oligonucleotide delivery systems for camptothecins
JP2023513302A (ja) 治療的に活性な作用物質を内皮へと送達するための脂質組成物およびその使用
CN120835876A (zh) 包括具有支化结构的电离脂质的脂质纳米粒制剂及其用途
Maclean et al. Immunoliposomes as targeted delivery vehicles for cancer therapeutics
CN113403313A (zh) 一种特异识别人PLK1位点的sgRNA、质粒、纳米复合物和应用
JP6384863B2 (ja) 脂質膜構造体
US20230301913A1 (en) Silyl lipids suitable for enhanced delivery of anti-viral therapeutics
HK40060954A (en) Lipid nanoparticle
CN120241640A (zh) 靶向纳米粒组合物及其应用